MedTrace Logo

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT05931276 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2540

Last updated 2026-01-09

No results posted yet for this study

Summary

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

Conditions

  • End-Stage Kidney Disease
  • End-Stage Renal Disease

Interventions

DRUG

Metoprolol Succinate

a dialyzable, beta-1 selective beta blocker

DRUG

Carvedilol

a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Areef Ishani, MD MS · Minneapolis VA Health Care System, Minneapolis, MN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2026-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05931276 on ClinicalTrials.gov